An investigator-initiated double-blind, parallel-group randomised controlled trial of GOLimumab and Methotrexate versus Methotrexate in very early PsA using clinical and whole body MRI outcomes: the GOLMePsA study.

Trial Profile

An investigator-initiated double-blind, parallel-group randomised controlled trial of GOLimumab and Methotrexate versus Methotrexate in very early PsA using clinical and whole body MRI outcomes: the GOLMePsA study.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2016

At a glance

  • Drugs Golimumab (Primary) ; Methotrexate
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms GOLMePsA
  • Sponsors Janssen
  • Most Recent Events

    • 17 Jun 2016 Planned End Date changed from 1 Jun 2017 to 1 Apr 2018.
    • 04 Dec 2015 Accrual to date is 1% according to United Kingdom Clinical Research Network record.
    • 21 Aug 2015 Status changed from not yet recruiting to recruiting according toEuropean Clinical Trials Database; (EudraCT2013-004122-28).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top